NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts [ID829]

Provisional matrix of consultees and commentators

Consultees	**Commentators (no right to submit or appeal)**
Company • Celgene (azacitidine) Patient/carer groups • Afiya Trust • Black Health Agency • Cancer Black Care • Cancer Equality • Cancer52 • Equalities National Council • HAWC • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Leukaemia Cancer Society • Leukaemia CARE • Macmillan Cancer Support • Maggie's Centres • Marie Curie Cancer Care • Muslim Council of Britain • Muslim Health Network • Rarer Cancers Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Professional groups • Association of Cancer Physicians • British Committee for Standards in Haematology • British Geriatrics Society • British Institute of Radiology • British Psychosocial Oncology Society • British Society for Haematology • Cancer Research UK • Royal College of General Practitioners	General • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium Possible comparator companies • Accord (cytarabine, doxorubicin, etopside) • Actavis (doxorubicin) • Aspen Pharma (mercaptopurine) • Bristol-Myers Squibb (etopside, hydroxycarbamide) • Janssen (decitabine, doxorubicin) • Hospira UK (cytarabine, doxorubicin, etopside) • medac UK (doxorubicin, etopside, hydroxycarbamide) • Merck Sharp & Dohme (doxorubicin) • Nordic (hydoxycarbamide) • Nova Laboratories (mercaptopurine) • Pfizer (cytarabine, doxorubicin) • Teva (doxorubicin)

Consultees	**Commentators (no right to submit or appeal)**
• Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiography • UK Clinical Pharmacy Association • UK Health Forum • UK Oncology Nursing Society <u>Others</u> • Department of Health • NHS England • NHS Mid Essex CCG • NHS Thurrock CCG • Welsh Government	• Wockhardt UK (doxorubicin) • Zentiva (daunorubicin) <u>Relevant research groups</u> • Cochrane Haematological Malignancies Group • Elimination of Leukaemia Fund • Institute of Cancer Research • Leuka • Leukaemia Busters • Leukaemia & Lymphoma Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research <u>Evidence Review Group</u> • Evidence Review Group tbc • National Institute for Health Research Health Technology Assessment Programme <u>Associated Guideline Groups</u> • National Collaborating Centre for Cancer <u>Associated Public Health Groups</u> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-company commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing company evidence submission to the Institute.

[1] Non-company consultees are invited to submit statements relevant to the group they are representing.